KL-A167

also known as Tagitanlimab

targets CD274 via inhibition

Developed for: nasopharyngeal carcinoma · breast cancer · breast carcinoma · castration-resistant prostate carcinoma · classic Hodgkin lymphoma · esophageal squamous cell carcinoma · estrogen-receptor positive breast cancer · gastric adenocarcinoma
+8 more
· gastroesophageal junction adenocarcinoma · head and neck squamous cell carcinoma · metastatic carcinoma · metastatic malignant neoplasm · non-small cell lung carcinoma · prostate adenocarcinoma · prostate neuroendocrine neoplasm · triple-negative breast carcinoma
Investigated by: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · West China Hospital · Henan Cancer Hospital · Shanghai Jiao Tong University School of Medicine · Sun Yat-sen University · Tianjin Medical University Cancer Institute and Hospital
+1 more
· Tianjin Medical University Second Hospital

Trials 12 · a red edge is where a trial was stopped

today NCT07701681 · Ph 2 NCT07492914 · Ph 2 NCT07371208 · Ph 2 NCT07179783 · Ph 2 NCT07109284 · Ph 2 NCT07153965 · Ph 2 NCT07108816 · Ph 2 NCT05445908 · Ph 2 NCT05294172 · Ph 3 NCT05351788 · Ph 2 NCT03848286 · Ph 2 NCT03580564 · Ph 2

2019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 211 trials
Phase 2	NCT07701681	Aug 2026 → Sep 2028 expected	esophageal squamous cell carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma	Sun Yat-sen University	Not yet recruiting	No outcome recorded
Phase 2	NCT07492914	May → Dec 2026 expected	head and neck squamous cell carcinoma	West China Hospital	Recruiting	No outcome recorded
Phase 2	NCT07371208	Dec 2025 → Aug 2028 expected	breast cancer	Shanghai Jiao Tong University School of Medicine	Recruiting	No outcome recorded
Phase 2	NCT07179783	Sep 2025 → Jun 2027 expected	castration-resistant prostate carcinoma, prostate adenocarcinoma, prostate neuroendocrine neoplasm	Tianjin Medical University Second Hospital	Recruiting	No outcome recorded
Phase 2	NCT07153965	Sep 2025 → Sep 2026 expected	triple-negative breast carcinoma	Tianjin Medical University Cancer Institute and Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT07109284	Sep 2025 → Jan 2028 expected	estrogen-receptor positive breast cancer	West China Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT07108816	Aug 2025 → Dec 2026 expected	—	Henan Cancer Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT05445908	Aug 2022 → Sep 2027 expected	breast carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Active not recruiting	No outcome recorded
Phase 2	NCT05351788	May 2022 → Aug 2026 overdue	non-small cell lung carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 2	NCT03848286	Mar 2019 → Jul 2021	metastatic malignant neoplasm, nasopharyngeal carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT03580564	Aug 2018 → Aug 2020	classic Hodgkin lymphoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Completed	No outcome recorded

Phase 31 trial
Phase 3	NCT05294172	Jun 2022 → Dec 2027 expected	metastatic carcinoma, nasopharyngeal carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Active not recruiting	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT05367635 Background	Mar 2022 → Jun 2026 overdue	cancer	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 21 trial
Phase 2	NCT07296809 Background	Jan 2026 → Dec 2028 expected	small cell lung carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Recruiting	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

Field	Value	Cited text
Known as	KL-A167	“Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167)” NCT07701681 ↗ 7 “combined with KL-A167 (900 mg, Day 1, every 2 weeks)” NCT07371208 ↗ NCT07296809 ↗ NCT03848286 ↗ NCT05445908 ↗ NCT05294172 ↗ NCT05351788 ↗ NCT03580564 ↗
Known as	Tagitanlimab	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07701681 ↗ 6 NCT07153965 ↗ NCT05367635 ↗ NCT07179783 ↗ NCT07109284 ↗ NCT07492914 ↗ NCT07108816 ↗
Action	Inhibit	“blocks the PD-1/PD-L1 signaling pathway” NCT07492914 ↗
Modality	Monoclonal antibody	“Humanized IgG1κ anti-PD-L1 monoclonal antibody” NCT07492914 ↗
Route	Intravenous	“900 mg intravenously (IV)” NCT03580564 ↗
Target	CD274	“Humanized IgG1κ anti-PD-L1 monoclonal antibody” NCT07492914 ↗